Evidence map›Paper›PMID 42474263›Full record

ReviewJournal of enzyme inhibition and medicinal chemistry2026

A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.

Yi-Ru Bai, Ruifang Li, Xin-Hui Zhang, Dong-Jie Seng, Ying Xu, Sai-Yang Zhang, Shuo Yuan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi-Ru BaiSchool of Chemistry and Chemical Engineering, Henan University of Technology, Zhengzhou, China.
Ruifang LiCollege of Biological Engineering, Henan University of Technology, Zhengzhou, China.
Xin-Hui ZhangCollege of Biological Engineering, Henan University of Technology, Zhengzhou, China.
Dong-Jie SengChildren's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.
Ying XuChildren's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.
Sai-Yang ZhangDepartment of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.ORCID 0000-0003-4395-8879
Shuo YuanSchool of Chemistry and Chemical Engineering, Henan University of Technology, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2025, the FDA approved 46 drug marketing applications, 31 of which were small molecule drugs. Despite the advancements in biotechnologies such as antibody drugs, RNA-based treatments, and antibody-drug conjugates, small molecule drugs remain dominant in new drug discovery. With progress in computer-aided drug design and scaffold-based drug design

Indexed as

Drug ApprovalSmall Molecule LibrariesDrug DesignHumansMolecular StructureStructure-Activity RelationshipUnited StatesUnited States Food and Drug AdministrationSmall Molecule Librariesdrug designmechanism of actionmolecular dockingsmall molecule drugStructure-activity relationship

Identifiers

PMID42474263
PMCPMC13386594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.